BioSpace News Archive

Cyclerion Therapeutics, Inc. and Beacon Biosignals announced an extended and expanded strategic partnership between the two companies.

Increasing demand for the medium (1.5T and 3T) field strength MRI system coupled with high investments in R&D of magnetic resonance imaging are fueling the market growth.

Thermo Fisher Scientific Inc., the world leader in serving science, announced that its Board of Directors has authorized a quarterly cash dividend of $0.26 per common share, payable on October 15, 2021, to shareholders of record as of September 15, 2021.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”) an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $4.00 per share, for gross proceeds of $25,000,000

Increasing demand for integrated ultrasonic aspirators coupled with high investments in R&D of ultrasonic aspirators is fueling the market growth.

INBRAIN Neuroelectronics, a company at the intersection of medtech, deeptech and digital health dedicated to developing the world’s first graphene-based intelligent neuroelectronic system, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.

OPKO Health, Inc. announced that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually July 13-14, 2021.

Breckenridge Pharmaceutical, Inc. announced that it has launched Zolpidem Tartrate Extended-Release Tablets, USP, manufactured by Centaur Pharmaceuticals Pvt. Ltd.

Alphanco Venture Corp. (TSXV: AVC.P) (the “Company” or “AVC”), a capital pool company listed on the TSX Venture Exchange (the “TSXV”), is pleased to announce that it has closed its proposed “Qualifying Transaction,” as defined under TSXV policies, being the acquisition of all of the outstanding shares (the “Transaction”) of Marvel Biotechnology Inc., (“Marvel Biotech”) effective June 14, 2021

Increasing prevalence of cancer, diabetes and cardiovascular diseases along with increasing adoption of high-content screening techniques.